NSPR InspireMD

InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6

InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6

Management to host conference call and webcast at 8am ET

TEL AVIV, Israel, July 30, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, August 6, 2019, to discuss financial results for the second quarter and six months ended June 30, 2019, and provide a corporate update.

Conference Call & Webcast:

Tuesday, August 6th @ 8am Eastern Time

Within the US:

Outside the US:

Conference ID:

Webcast: 		877-451-6152

201-389-0879

13692587



About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.

InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

EN
30/07/2019

Underlying

NSPRInspireMD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InspireMD

 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinic...

InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure TEL AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that early results from the investigator-initiated SIBERIA randomized clinical t...

June 25, 2020 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces Publication of 12-Month Results of CGuardâ„¢ EPS P...

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that 12-month PARADIGM trial results have been published in the EuroIntervention jour...

June 10, 2020 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Optio...

InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the closing, on June 5, 2020, of its $11.5 million follow-on underwritten public offering, which included $1.5 million from the exercise, in full, by the underwriter of its over-allotment option for the offering. Pur...

June 8, 2020 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public O...

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 22,222,200 units at a price to the public of $0.45 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $10.0 million from the offering, assuming no exercise of the underwriter’s option to purchase additional...

June 3, 2020 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces First Quarter 2020 Financial Results

InspireMD Announces First Quarter 2020 Financial Results First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today, May 12, at 8:30am ET TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the first quarter ended Ma...

May 12, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch